Xiumei Liu

Xiumei Liu

Auto-generated profile, based on publicly available information

Xiumei Liu

Stem Cell Clinical Research Center, National Joint Engineering Laboratory, Regenerative Medicine The First Affiliated Hospital of Dalian Medical University Dalian Liaoning China

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 September 2005 in The Journal of Physical Chemistry B
Verified
Journal Article
Open access
Gang YangGang Yang
Gang Yang
XHXiuwen Han
Xiuwen Han
WZWeiping Zhang
Weiping Zhang
XLXiumei Liu
Xiumei Liu
PYPengyu Yang
Pengyu Yang
XBXinhe Bao
Xinhe Bao
Variable-temperature NMR experiments and ab initio density functional calculations were carried out to investigate the conformation interconversion of novel chiral 3-alkyl-3,4-dihydro-2H-benzo[1,4]oxazine derivatives. With CDCl3 as the solvent, the coalescence temperatures of H2, H3, H11, and H19 of product 1 are about 289, 304, 292, and 316 K, with the corresponding activation free energies at 58.0 ± 6.7, 60.9 ± 7.1, 58.3 ± 6.8, and 59.6 ± 6.9 kJ·mol-1, respectively. When dimethyl sulfoxide (DMSO-d6) was used as the solvent, 1H and 13C NMR signals were completely assigned at 375 K. The effects of solvent and temperature were investigated through a polarizable continuum model. At each theoretical level (MP2 or B3LYP), the changing tendencies of the calculated activation free energies and interconversion rates agree well with those of the NMR results. In addition, the interconversion rate at each specified temperature was calculated to be about 1.5 times faster in DMSO-d6 than in CDCl3. Accordingly, we failed to observe the coalescence phenomena of H3 and H19 in DMSO-d6 by NMR measurements from 296 to 375 K. The substitution effect at the R1−R5 positions was considered using density functional calculations, with the activation barriers decreasing as follows: product 6 > 3 > 1 > 7 > 2. This sequence is consistent with that of the reaction heats, except for product 7, implying that the interconversion processes may be thermodynamically controlled. Surprisingly, the substituted groups near the acetyl group in product 2 and 7 do not elevate the activation barrier but, instead, lower it somewhat, with the possible reasons for this provided in the paper.

1 March 2019 in Gene
Verified
Journal Article
Closed access
YSYan Sun
Yan Sun
JLJinxiang Liu
Jinxiang Liu
BWBo Wang
Bo Wang
XLXiumei Liu
Xiumei Liu
XDXinxin Du
Xinxin Du
QZQuanqi Zhang
Quanqi Zhang

28 April 2026 in Health Science Reports
Verified
Journal Article
Open access
XLXiumei Liu
Xiumei Liu
WCWeigong Chen
Weigong Chen
CXChengqi Xin
Chengqi Xin
ZWZexu Wang
Zexu Wang
KYKaiyu Yi
Kaiyu Yi
Jing LiuJing Liu
Jing Liu
Background and Aims: Understanding genetic alterations in lung cancer remains challenging due to tumor heterogeneity and malignancy. This study aimed to investigate somatic variations and immune‐related biomarkers in Chinese patients with NSCLC. Methods: This retrospective study involved Chinese patients with NSCLC from October 2019 to December 2024. A total of 554 pathological specimens were analyzed using targeted NGS panels. Fisher's exact test (two‐sided, 95% confidence interval) was applied to assess statistical significance. The functional impact of certain mutations was validated in lung cancer cell lines. Results: A total of 1302 genetic variations were identified. The most frequently altered genes included EGFR , TP53 , KRAS , PIK3CA , STK11 , ERBB2 , BRAF , CTNNB1 , MET , and PTEN . Enrichment analysis indicated that these genetic alterations were primarily concentrated in the EGFR, PI3K‐AKT, microRNAs, P53, MAPK, ErbB, VEGF, JAK‐STAT, and FoxO signaling pathways. Several co‐occurring and mutually exclusive mutations were identified among the top altered genes. The co‐mutation of PDGFRA and MET, or NRAS and PTEN in A549 cells, promoted cell proliferation and invasion compared with the control cells. Among patients receiving immunotherapy, the objective response rates were significantly higher in the TMB‐high group than in the TMB‐low group (62.5% vs. 34.2%), as well as in the heterozygous HLA‐I group compared to the homogenous HLA‐I group (51.6% vs. 25.9%). Analysis showed that TMB status was correlated with the tumor‐infiltrating immune cells in the TCGA LUAD and LUSC datasets. TP53 mutations were more prevalent in males ( p = 0.03) and associated with squamous cell carcinomas ( p = 0.007), whereas EGFR mutations were more common in females ( p < 0.001) and associated with lung adenocarcinomas ( p = 0.029). Conclusion: Our findings suggest that a high TMB combined with a heterozygous HLA‐I genotype serves as an effective biomarker for predicting the efficacy of immunotherapy in Chinese patients with NSCLC.